Literature DB >> 7957806

Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia.

A Mellemgaard1, C H Geisler, H H Storm.   

Abstract

Patients with chronic lymphocytic leukemia (CLL) are known to to have an increased incidence of secondary cancers. We investigated the occurrence of secondary cancers in 7391 patients with CLL diagnosed between 1955 and 1988. The observed number of cancer cases was compared with the expected number of cancers calculated from national cancer incidence rates. The overall risk of cancer was significantly increased among persons with CLL. The standardized incidence ratios (ratio between the observed and the expected numbers) were 2.0 for men and 1.2 for women. Increased risks were found for cancer of the lung and prostate in men (RR = 2.0 and 1.5 respectively), renal parenchyma in both sexes (RR = 2.8 for men, RR = 3.6 for women) non-melanoma skin cancer in both sexes (RR = 4.7 for men, RR = 2.4 for women) and sarcomas (RR = 3.3 for men, RR = 2.8 for women). Although an increased risk of cancer is to be expected solely because individuals with CLL are being physically examined frequently, it appears that the risk is significantly increased for a number of cancer sites in persons with CLL.

Entities:  

Mesh:

Year:  1994        PMID: 7957806     DOI: 10.1111/j.1600-0609.1994.tb00192.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

1.  Concurrent occurrence of three neoplasms including non-Hodgkin's lymphoma, renal cell carcinoma and leiomyoma in the same kidney.

Authors:  D Dinçol; A Arican; A Ensari; S Akyar; Y Bedük; A Cengiz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

2.  Merkel cell carcinoma of the eyelid in association with chronic lymphocytic leukaemia.

Authors:  N Sinclair; K Mireskandari; J Forbes; J Crow
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

3.  Increased metastasis of malignant fibrous histiocytoma in patients with chronic lymphocytic leukemia and non-hodgkin lymphoma.

Authors:  Agnieszka W Kubica; Peter S Rose; Amy L Weaver; Jerry D Brewer
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

4.  Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.

Authors:  Lindsay M Morton; Rochelle E Curtis; Martha S Linet; Elizabeth C Bluhm; Margaret A Tucker; Neil Caporaso; Lynn A G Ries; Joseph F Fraumeni
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

Review 5.  Photoimmunology.

Authors:  Craig A Elmets; Cather M Cala; Hui Xu
Journal:  Dermatol Clin       Date:  2014-05-05       Impact factor: 3.478

Review 6.  Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia.

Authors:  Constantin A Dasanu; Doru T Alexandrescu
Journal:  MedGenMed       Date:  2007-11-15

7.  Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer.

Authors:  Caroline Besson; Amy Moore; Wenting Wu; Claire M Vajdic; Silvia de Sanjose; Nicola J Camp; Karin E Smedby; Tait D Shanafelt; Lindsay M Morton; Jerry D Brewer; Lydia Zablotska; Eric A Engels; James R Cerhan; Susan L Slager; Jiali Han; Sonja I Berndt
Journal:  Int J Epidemiol       Date:  2021-08-30       Impact factor: 7.196

8.  Eyelid carcinoma in patients with systemic lymphoma.

Authors:  Debraj Shome; Diana Bell; Bita Esmaeli
Journal:  J Ophthalmic Vis Res       Date:  2010-01

9.  Acalabrutinib in treatment-naive chronic lymphocytic leukemia.

Authors:  John C Byrd; Jennifer A Woyach; Richard R Furman; Peter Martin; Susan O'Brien; Jennifer R Brown; Deborah M Stephens; Jacqueline C Barrientos; Stephen Devereux; Peter Hillmen; John M Pagel; Ahmed Hamdy; Raquel Izumi; Priti Patel; Min Hui Wang; Nitin Jain; William G Wierda
Journal:  Blood       Date:  2021-06-17       Impact factor: 25.476

Review 10.  Second neoplasms in patients with chronic lymphocytic leukemia.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.